{"id":"paclitaxel-gemcitabine-liposomal-doxorubicin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Paclitaxel stabilizes microtubules, preventing cell division, while Gemcitabine is incorporated into DNA, causing chain termination. Liposomal doxorubicin's intercalation into DNA inhibits topoisomerase II, leading to DNA damage and apoptosis.","oneSentence":"Paclitaxel inhibits microtubule dynamics, Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and Liposomal doxorubicin is an anthracycline antibiotic that intercalates DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:27.814Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer"}]},"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT07254091","phase":"EARLY_PHASE1","title":"Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2026-01-30","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT01970722","phase":"PHASE1","title":"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-05-19","conditions":"FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma","enrollment":40},{"nctId":"NCT06619236","phase":"PHASE3","title":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2025-02-07","conditions":"Platinum-resistant Ovarian Cancer","enrollment":530},{"nctId":"NCT05481645","phase":"PHASE2","title":"Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-26","conditions":"Advanced Endometrial Cancer, Sarcoma of Uterus","enrollment":71},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT03651206","phase":"PHASE2, PHASE3","title":"Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2020-07-15","conditions":"Ovarian Carcinosarcoma, Endometrial Carcinosarcoma","enrollment":138},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT05092360","phase":"PHASE3","title":"Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)","status":"TERMINATED","sponsor":"Mural Oncology, Inc","startDate":"2022-01-10","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":456},{"nctId":"NCT06023862","phase":"PHASE2","title":"A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-01-22","conditions":"Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms","enrollment":198},{"nctId":"NCT06292286","phase":"NA","title":"Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2023-11-01","conditions":"Recurrent Ovarian Carcinoma","enrollment":18},{"nctId":"NCT06990503","phase":"PHASE3","title":"SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT06834672","phase":"PHASE3","title":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-03-17","conditions":"Ovarian, Primary Peritoneal, Fallopian Tube Cancer","enrollment":450},{"nctId":"NCT04274426","phase":"PHASE2","title":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AGO Research GmbH","startDate":"2021-10-13","conditions":"Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma","enrollment":136},{"nctId":"NCT06828354","phase":"PHASE3","title":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT02489903","phase":"PHASE2","title":"RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2015-06","conditions":"Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors","enrollment":139},{"nctId":"NCT04421547","phase":"PHASE3","title":"Efficacy of Letrozole in Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-06-22","conditions":"Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT03674424","phase":"PHASE2","title":"Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2018-06-01","conditions":"Non-metastatic Muscle Invasive Bladder Cancer","enrollment":137},{"nctId":"NCT03563144","phase":"PHASE2","title":"QUILT-3.088: NANT Pancreatic Cancer Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT03632798","phase":"PHASE3","title":"Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Cordgenics, LLC","startDate":"2018-08-01","conditions":"Recurrent Ovarian Cancer","enrollment":""},{"nctId":"NCT02891824","phase":"PHASE3","title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2016-09-22","conditions":"Ovarian Cancer","enrollment":614},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT02312245","phase":"PHASE2","title":"Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-21","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":13},{"nctId":"NCT06713057","phase":"PHASE2","title":"Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-12-01","conditions":"Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer","enrollment":20},{"nctId":"NCT04516447","phase":"PHASE1","title":"A Study of ZN-c3 in Patients With Ovarian Cancer","status":"RECRUITING","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","startDate":"2020-10-26","conditions":"Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":140},{"nctId":"NCT06102824","phase":"PHASE2","title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-10-01","conditions":"HER2-negative Breast Cancer, Advanced Breast Cancer","enrollment":252},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT03678883","phase":"PHASE2","title":"9-ING-41 in Patients with Advanced Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actuate Therapeutics Inc.","startDate":"2019-01-04","conditions":"Cancer, Pancreatic Cancer, Sarcoma","enrollment":350},{"nctId":"NCT06600841","phase":"PHASE2","title":"Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-10-01","conditions":"Platinum-resistant Ovarian Cancer (PROC), Immunotherapy","enrollment":37},{"nctId":"NCT03598270","phase":"PHASE3","title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2018-11-21","conditions":"Recurrent Ovarian Carcinoma","enrollment":417},{"nctId":"NCT01696032","phase":"PHASE2","title":"SGI-110 in Combination With Carboplatin in Ovarian Cancer","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2012-09","conditions":"Ovarian Cancer","enrollment":120},{"nctId":"NCT03949283","phase":"PHASE3","title":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cordgenics, LLC","startDate":"2019-07-26","conditions":"Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer","enrollment":150},{"nctId":"NCT05684731","phase":"PHASE1","title":"Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-02-01","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT06531447","phase":"PHASE2","title":"First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The National Center of Oncology, Azerbaijan","startDate":"2014-05","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT01279291","phase":"PHASE1","title":"Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer","status":"TERMINATED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-01","conditions":"Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms","enrollment":22},{"nctId":"NCT06204614","phase":"EARLY_PHASE1","title":"Drug Screening Using IMD in Bladder Cancer","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2024-02-14","conditions":"Muscle Invasive Bladder Urothelial Carcinoma","enrollment":18},{"nctId":"NCT00679029","phase":"PHASE2","title":"Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2008-05-02","conditions":"HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer","enrollment":15},{"nctId":"NCT00657878","phase":"PHASE3","title":"Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2008-11","conditions":"Ovarian Cancer","enrollment":215},{"nctId":"NCT02272790","phase":"PHASE2","title":"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-30","conditions":"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation","enrollment":95},{"nctId":"NCT05774886","phase":"PHASE1","title":"Implantable Microdevice for TNBC - Pilot Study","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-05","conditions":"Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III","enrollment":""},{"nctId":"NCT03472274","phase":"PHASE2","title":"Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","status":"COMPLETED","sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","startDate":"2018-10-25","conditions":"Bladder Cancer","enrollment":101},{"nctId":"NCT05255471","phase":"PHASE3","title":"MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2022-01-21","conditions":"Ovarian Cancer","enrollment":200},{"nctId":"NCT01802749","phase":"PHASE3","title":"Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2013-11","conditions":"Recurrent Ovarian Cancer","enrollment":406},{"nctId":"NCT00128856","phase":"PHASE2","title":"Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2003-03","conditions":"Breast Cancer","enrollment":46},{"nctId":"NCT01646034","phase":"PHASE3","title":"High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2014-09","conditions":"Breast Cancer","enrollment":74},{"nctId":"NCT02282020","phase":"PHASE3","title":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-06","conditions":"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity","enrollment":266},{"nctId":"NCT03905902","phase":"PHASE3","title":"DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma","status":"WITHDRAWN","sponsor":"SOTIO a.s.","startDate":"2021-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT00193206","phase":"PHASE2","title":"Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2005-09","conditions":"Breast Cancer","enrollment":123},{"nctId":"NCT03467178","phase":"PHASE2","title":"Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2018-07-30","conditions":"Recurrent, Platinum-resistant Ovarian Cancer","enrollment":119},{"nctId":"NCT04679064","phase":"PHASE3","title":"Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-12-01","conditions":"Ovarian Cancer","enrollment":427},{"nctId":"NCT02903004","phase":"PHASE3","title":"Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2016-04-11","conditions":"Ovarian Neoplasms","enrollment":242},{"nctId":"NCT02822157","phase":"PHASE2","title":"Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-08","conditions":"Ovarian Epithelial Cancer","enrollment":160},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00478361","phase":"PHASE2","title":"Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04","conditions":"Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer","enrollment":40},{"nctId":"NCT02580253","phase":"PHASE2","title":"Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation","status":"WITHDRAWN","sponsor":"Zhejiang University","startDate":"2017-11-01","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT01248962","phase":"PHASE2","title":"Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-11","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":146},{"nctId":"NCT04055038","phase":"PHASE2, PHASE3","title":"Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2019-09-01","conditions":"Ovarian Cancer, Ovarian Neoplasms, Serous Adenocarcinoma","enrollment":164},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT00011986","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2001-01","conditions":"Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer","enrollment":4312},{"nctId":"NCT03668418","phase":"","title":"Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2018-06-01","conditions":"Liver Cancer, Pancreatic Cancer, Gastric Cancer","enrollment":120},{"nctId":"NCT00954512","phase":"PHASE1, PHASE2","title":"Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Neoplasms","enrollment":15},{"nctId":"NCT02331251","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2014-12","conditions":"Advanced Cancer, Breast Cancer, Sarcoma","enrollment":81},{"nctId":"NCT03539328","phase":"PHASE2","title":"Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2018-06","conditions":"Ovarian Cancer","enrollment":138},{"nctId":"NCT01698281","phase":"PHASE2","title":"Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"AEterna Zentaris","startDate":"2012-12","conditions":"Breast Cancer","enrollment":7},{"nctId":"NCT00093795","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2004-10","conditions":"Breast Cancer","enrollment":4894},{"nctId":"NCT01593228","phase":"PHASE3","title":"Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Solid Tumors","enrollment":37},{"nctId":"NCT01156753","phase":"PHASE2","title":"A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer","status":"COMPLETED","sponsor":"Celldex Therapeutics","startDate":"2010-07","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT01188499","phase":"PHASE1, PHASE2","title":"Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"TetraLogic Pharmaceuticals","startDate":"2010-10","conditions":"Cancer","enrollment":176},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT01121406","phase":"PHASE2","title":"BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-04","conditions":"Ovarian Neoplasms","enrollment":110},{"nctId":"NCT01455532","phase":"PHASE1","title":"A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-11","conditions":"Neoplasm Malignant","enrollment":59},{"nctId":"NCT00070278","phase":"PHASE3","title":"Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2005-01","conditions":"Breast Cancer","enrollment":800},{"nctId":"NCT00039546","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery","status":"UNKNOWN","sponsor":"Cancer Research Campaign Clinical Trials Centre","startDate":"2001-08","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10},{"nctId":"NCT00003105","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1997-09","conditions":"Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter","enrollment":30},{"nctId":"NCT00003342","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1997-12","conditions":"Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter","enrollment":30},{"nctId":"NCT00003133","phase":"PHASE1","title":"Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1997-09","conditions":"Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter","enrollment":30},{"nctId":"NCT00003540","phase":"PHASE2","title":"Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-06","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT01204996","phase":"PHASE1","title":"A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2010-05","conditions":"Cancer","enrollment":53},{"nctId":"NCT00378313","phase":"PHASE2","title":"A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2001-11","conditions":"Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"paclitaxel/Gemcitabine/Liposomal doxorubicin","genericName":"paclitaxel/Gemcitabine/Liposomal doxorubicin","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel inhibits microtubule dynamics, Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and Liposomal doxorubicin is an anthracycline antibiotic that intercalates DNA. Used for Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}